2020 marks ten years since the passage of the Biologics Price Competition and Innovation Act. The US biosimilars market continues to maintain its momentum, but important questions and barriers remain.
The ACI’s 11th Annual Summit on Biosimilars & Innovator Biologics is the industry’s foremost event directed to the legal, regulatory and commercial aspects of the biosimilars marketplace. The speaking faculty consists of top innovator and biosimilar makers, government representatives and leading law firms who will discuss critical industry developments and provide skilled insights into the design and execution of successful biosimilars strategies.
WilmerHale Partner Kevin Prussia will speak on the panel “Key Litigations and Decisions at the Federal Circuit, the District Courts and the PTAB Affecting the Biologics Landscape” alongside Venable Partner Christopher Borello, Paul Hastings Partner Eric Dittmann, Biocon Biologics Chief IP Counsel Arshad Jamil and Honigman LLP Partner Gregory Morris.
A livestream option for this event will be available.